# RNA (Atrium Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Atrium Therapeutics, Inc. reported $264.0M in total assets through September 30, 2026 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/RNA
- Markdown: https://convexityos.com/fundamentals/RNA.md
- SEC CIK: 0002093101
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:47 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002093101&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2026 | -- | Sep 30, 2026 |
| Operating Income | FY 2026 | -- | Operating profit |
| Net Income | FY 2026 | -- | GAAP bottom line |
| Diluted EPS | FY 2026 | -- | Split-adjusted |
| Free Cash Flow | FY 2026 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $232.1M | Total debt: $679K |

## Income Statement

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $15.32M | $3.00M | $19.64M | $12.34M | $3.85M | $1.57M |
| Research & Development | $13.80M | $15.34M | $16.66M | $9.75M | $13.29M | $6.94M |
| Total Operating Expenses | $21.95M | $25.62M | $36.91M | $12.55M | $16.71M | $9.03M |
| **Operating Income** | -$6.63M | -$22.62M | -$17.28M | -$213K | -$12.86M | -$7.45M |
| **EBITDA** | -$6.28M | -$22.27M | -$17.13M | -$144K | -$12.79M | -$7.40M |
| Interest Income | $2.19M | $2.10M | -- | $0 | $0 | -- |
| Income Before Tax | -$4.27M | -- | -- | -$213K | -- | -- |
| Income Tax Expense | $0 | -- | -- | -$176K | -- | -- |
| **Net Income** | -$4.27M | -$20.19M | -$16.63M | -$37K | -$12.88M | -$7.45M |
| Basic EPS | -$0.25 | -$1.18 | -$0.97 | $0.00 | -$0.75 | -$0.44 |
| **Diluted EPS** | -$0.25 | -$1.18 | -$0.97 | $0.00 | -$0.75 | -$0.44 |
| Basic Shares Outstanding | 17.0M | 17.1M | 17.1M | 17.1M | 17.1M | 17.1M |
| Diluted Shares Outstanding | 17.0M | 17.1M | 17.1M | 17.1M | 17.1M | 17.1M |

## Balance Sheet

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $44.56M | $72.33M | $267.8M | $0 |
| Short-Term Investments | $187.5M | $191.6M | -- | $0 |
| **Cash & Short-Term Investments** | $232.1M | $263.9M | $267.8M | $0 |
| Other Current Assets | $2.13M | $6.33M | $138K | $1.31M |
| **Total Current Assets** | $258.1M | $275.1M | $285.6M | $2.85M |
| Property, Plant & Equipment, Net | $4.19M | $4.07M | $4.34M | $2.72M |
| Other Non-Current Assets | $1.12M | -- | -- | $0 |
| **Total Non-Current Assets** | $5.93M | $5.46M | $6.79M | $5.51M |
| **Total Assets** | $264.0M | $280.5M | $292.4M | $8.35M |
| Accounts Payable | $782K | $3.51M | $807K | $4.40M |
| Deferred Revenue (Current) | $9.45M | $9.04M | $9.34M | $21.64M |
| **Total Current Liabilities** | $24.66M | $31.51M | $21.91M | $41.80M |
| Deferred Revenue (Non-Current) | $32.92M | $33.65M | $36.35M | $28.69M |
| Other Non-Current Liabilities | $1.38M | $775K | $0 | $574K |
| **Total Non-Current Liabilities** | $34.30M | $34.43M | $36.35M | $29.27M |
| **Total Liabilities** | $58.97M | $65.94M | $58.26M | $71.07M |
| **Total Debt (incl. Leases)** | $679K | $1.68M | $2.68M | $3.67M |
| Common Stock | $16K | $16K | $16K | $0 |
| Retained Earnings | -$12.32M | -$8.06M | $12.13M | $0 |
| Accumulated Other Comp. Income | -$347K | -$235K | -- | $0 |
| **Total Stockholders' Equity** | $205.0M | $214.6M | $234.1M | -$62.71M |
| Total Equity | $205.0M | $214.6M | $234.1M | -$62.71M |

## Cash Flow Statement

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$4.27M | -$20.19M | -$16.63M | -$37K | -$12.88M | -$7.45M |
| Depreciation & Amortization | $352K | $343K | $151K | $69K | $79K | $53K |
| Stock-Based Compensation | $1.12M | $893K | $12.21M | $1.22M | $1.70M | $1.21M |
| Change in Receivables | -- | -- | -$15.00M | -- | -- | $0 |
| Change in Payables | -$2.73M | $2.71M | -$3.59M | $140K | -$258K | $37K |
| **Operating Cash Flow** | -$25.37M | -$3.93M | -$31.14M | $1.13M | -$11.91M | -$11.10M |
| Capital Expenditure | -$415K | -$36K | -$2.10M | -$300K | -$266K | $0 |
| **Free Cash Flow** | -$25.78M | -$3.96M | -$33.24M | $833K | -$12.17M | -$11.10M |
| **Investing Cash Flow** | $3.90M | -$191.6M | -$2.10M | -$300K | -$266K | $0 |
| **Financing Cash Flow** | -$6.30M | $0 | $301.5M | -$833K | $12.17M | $11.10M |
| **Net Change in Cash** | -$27.77M | -$195.5M | $268.3M | $0 | $0 | $0 |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Current Ratio | 10.46x | 8.73x | 13.04x | -- | -- | -- |
| Quick Ratio | 9.41x | 8.38x | 12.23x | -- | -- | -- |
| Debt to Equity | 0.00x | 0.01x | 0.01x | -- | -- | -- |
| **Revenue Growth (YoY)** | +24.2% | -21.9% | +1148.3% | -- | -- | -- |
| Operating Cash Flow Growth (YoY) | -2339.0% | -- | -- | -- | -- | -- |
| Free Cash Flow Growth (YoY) | -3195.2% | -- | -- | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
